Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm

Current Status and Future Directions

Luca Bettari, MD; Mona Fiuzat, PharmD; Richard Becker, MD; G. Michael Felker, MD; Marco Metra, MD; Christopher M. O’Connor, MD

Heart failure (HF) represents a major and growing public health problem because of its prevalence, incidence, morbidity, mortality, and economic costs. The prevalence of HF is 2% to 3% of the general population. Five million Americans are affected, with >550,000 cases diagnosed each year. The mortality rate from severe HF remains >60% within 5 years of diagnosis, and 50% of hospitalized patients with HF require readmission within 6 months of discharge. In the US estimated costs amount to >$35 billion per year.

Although several therapies (eg, β-blockers, angiotensin-converting enzyme [ACE] inhibitors, and cardiac resynchronization therapy) have been proven effective in improving HF outcomes, many unanswered questions about optimal treatment remain. One area of ongoing uncertainty is the appropriate role for antithrombotic therapy in patients with HF. Observational data suggest that patients with HF have an increased venous thromboembolism (VTE) risk (deep venous thromboembolism [DVT], pulmonary embolism [PE], peripheral arterial thromboembolism, and stroke). These epidemiological findings are supported by multiple mechanisms that can contribute to a hypercoagulable state in patients with HF. Despite this increased risk of VTE, the role of antithrombotic therapy remains unclear. In this article, we provide an overview of epidemiology, pathophysiology, clinical trial data, and therapeutic recommendations for prevention of thromboembolism in HF.

Search Strategy

We searched PubMed for articles published between 1958 and 2010 using the following search terms: epidemiology of heart failure, thromboembolism and heart failure, thrombogenesis and heart failure, anticoagulation in heart failure, antiplatelet agent and heart failure, aspirin and heart failure, bleeding risk and anticoagulation, and aspirin and angiotensin-converting enzyme inhibitors. We also studied abstracts from national and international cardiovascular meetings to identify unpublished studies using the key words anticoagulation and dilated cardiomyopathy.

Epidemiology

Data from published observational studies and secondary analyses of randomized controlled trials (RCTs) indicate that patients with HF patients have a higher risk for VTE than the general population.

Observational Cohorts

DVT and PE

Several case-cohort studies have shown that HF is associated with a 2- to 3-fold increased risk of DVT and PE compared with other medical conditions. Retrospective analyses report an annual VTE incidence of 1.0% to 4.5% in patients with HF. In RCTs of thromboprophylaxis in hospitalized patients with HF followed for 90 days, DVT rates ranged from 4.0% to 14.6%. The Prophylaxis in Medical Patients With Enoxaparin trial evaluated VTE incidence in hospitalized patients with (n=353) and without (n=749) HF during a follow-up of 14 days after discharge and found that 15% of patients with HF not treated with enoxaparin developed VTE. Beemath et al, using data from the National Hospital Discharge Survey, found an increased risk of VTE in hospitalized patients with HF compared to those without HF, with a relative risk of 2.15 for PE and 1.21 for DVT. Darze et al found that 9% of patients with HF admitted to the coronary care unit developed PE during their hospital stay and that 44% of those patients had concomitant DVT.

Stroke

The annual rate of stroke in the general population is 0.1% to 0.5% at age 80 years, whereas in the HF population, it is 1.0% to 3.5%, with a possible relationship between low left ventricular ejection fraction (LVEF) and stroke risk. In the Northern Manhattan Study, 270 patients hospitalized with initial occurrence of ischemic stroke were compared with 288 matched controls. Decreased LVEF of any severity was found to be associated with ischemic stroke, even after adjusting for other risk factors (P<0.0001).

LV Thrombi

There is an increased risk for LV thrombus formation in HF. LVEF is the most important risk factor for thrombus forma-
tion, whereas severe mitral regurgitation may have a protective effect by decreasing blood stasis.\textsuperscript{13} Notably, up to 30% of patients with HF may have evidence of intracardiac thrombi on echocardiography, but their presence may not be predictive of systemic embolism, and anticoagulation has not been associated with a clear VTE reduction.\textsuperscript{14} Studies suggest an increased embolic risk associated with LV thrombi, especially when they protrude into the LV cavity and are associated with apical aneurysm or are mobile.\textsuperscript{15}

### Retrospective Analyses of RCTs

In the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment cohorts, VTE annual incidence (stroke, PE, and peripheral emboli) in patients with HF (LVEF <35%) in sinus rhythm was 2.4% and 1.8% in women and men, respectively. Multivariate analysis found that lower LVEF was associated with VTE risk only in women, with a 53% increased risk rate for every 10% LVEF reduction.\textsuperscript{16}

In the Veterans Affairs Vasodilator-Congestive Heart Failure Trials (V-HeFT I and II), which included both patients in sinus rhythm and with atrial fibrillation (AF), VTE incidence was 2.7 and 2.1 per 100 patient-years in V-HeFT I and II, respectively. Notably, 15% of the patients had AF, but this was not independently associated with VTE increase. These analyses also revealed that individuals experiencing VTE have greater HF severity (lower peak oxygen consumption [\(P<0.03\) and \(P<0.001\)] and lower LVEF [\(P=0.1\) and \(P=0.07\) in V-HeFT I and II, respectively]).\textsuperscript{6}

The Survival and Ventricular Enlargement (SAVE) trial enrolled 2231 patients with LV dysfunction after myocardial infarction (MI). The VTE annual rate (fatal and nonfatal stroke) was 1.5%. The estimated 5-year rate of stroke was 8.1%, with a 2-fold increase in stroke risk in patients with LVEF \(\leq\)28% and an 18% stroke risk increase for every 5% LVEF reduction.\textsuperscript{17}

In an analysis of the Sudden Cardiac Death-Heart Failure Trial, which excluded all patients with AF at the time of randomization, 3.4% of the 2114 patients experienced VTE. A trend toward an increase in incidence of embolic complications with lower LVEF was observed (3.5%, 3.6%, and 4.6% with LVEF 30% to 35%, 20% to 30%, and <20%, respectively). Overall, the 4-year survival analysis found that VTE rate was 4.0%, with an annual incidence of 1%.\textsuperscript{11} VTE incidence in HF RCTs is summarized in Table 1.

### Pathophysiology

The mechanisms leading to increased VTE risk in HF are multifactorial and relate to the Virchow Triade (abnormal blood constituents, blood flow, and vessel wall), which defines a hypercoagulable state\textsuperscript{18} (Figure 1). Blood constituent abnormalities are due to platelet and thrombin activation, which result in abnormal coagulation and increased plasma viscosity. In HF, there is evidence of reduced platelet volume, and greater platelet activation.\textsuperscript{19} Patients with HF demonstrate high levels of circulating fibrinogen, fibrinopeptide A, and D-dimer determined by high plasma norepinephrine concentration or low LVEF.\textsuperscript{20} Higher levels of angiotensin and endothelin commonly seen in patients with HF patients increase levels of von Willebrand factor (VWF). Elevated tissue plasminogen activator antigen levels have been shown to be an independent predictor of prognosis in patients with chronic stable HF. C-reactive protein levels can directly increase tissue factor and induce expression of cytokines with prothrombotic properties.\textsuperscript{21} Moreover, patients with HF show increased plasma concentration of \(\beta\)-thromboglobulin, platelet-bound P-selectin, platelet/endothelial cell adhesion molecule-1, platelet surface P-selectin, CD40L, and osteonectin. Thrombin activity has 2 highly sensitive markers that are fibrinopeptide A and thrombin-antithrombin III complexes.\textsuperscript{22} An increase in these factors is associated with increased VTE risk. Patients with HF also show high levels of fibrinogen and D-dimer, which correlate with the severity of the disease, and decreased levels of ADAMTS-13, a protease that cleaves VWF,\textsuperscript{23} thereby increasing circulating VWF. Indeed, de-
increased ADAMTS13 and increased circulating VWF were found to be significant predictors of clinical events in HF.24

Blood flow abnormalities are due to blood stasis because of the dilatation of cardiac chambers, reduced myocardial contractility, increased intracardiac and central venous pressures, and immobility due to severe HF. Chronic impairment of blood flow leads to tissue hypoperfusion and related ischemic metabolic changes that, in turn, support the development of permanent oxidative stress leading to the activation of platelets, leukocytes, and endothelial cells and production of proinflammatory cytokines.25 Because the endothelium is oxygenated directly by the blood in the vessel lumen, endothelial cells are particularly sensitive to ischemia. Recent studies have shown that ischemia induces expression of the adhesion molecule P-selectin on endothelial cells, which, subsequently, stimulates leukocytes to infiltrate the ischemic vessel wall and upregulate tissue factor expression on their surfaces.26 Moreover, downregulation of thrombomodulin at the endothelial surface, mediated by interleukin-1 and tumor necrosis factor α, decreases the natural anticoagulant protein C effects.27 Additionally, increased plasma concentrations of tumor necrosis factor α and interleukin-1 inhibit the endogenous fibrinolytic system, resulting in inadequate fibrin removal and possibly thrombosis. The increase of intracardiac and central venous pressures inhibits the release of atrial thrombomodulin, resulting in an increase in local thrombin production. Kapur et al28 demonstrated that acute elevation of left atrial pressure inhibits production of atrial thrombomodulin, resulting in downregulation of endocardial thrombomodulin expression and thus increasing local thrombin production.

Vessel wall abnormalities are due to inflammation, endothelial dysfunction, and neurohormonal activation. Endothelial dysfunction with decreased levels of nitric oxide causes increased monocyte and platelet adhesion. Tissue factor, a procoagulant, can be increased by tumor necrosis factor α and interleukin-1, which have been shown to be higher in HF. Activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system, which is fundamental to the development and progression of HF, is characterized by increased release of catecholamines, angiotensin II, and aldosterone. These directly influence the metabolism and function of endothelial cells, decreasing nitric oxide bioavailability and prostacyclin production, and increase VWF release, thromboxane A2, and endothelin, which may contribute to increased peripheral vasoconstriction, exacerbation of vessel wall ischemia, and promotion of thrombogenesis.29

Taken together, these data strongly suggest an extensive cross-talk between inflammatory and coagulation pathways. Additionally, they provide a link between inflammation and thrombosis in HF, making HF a prothrombotic condition.

**Evidence for Antithrombotic Therapy in HF**

**Retrospective Analyses**

In a post hoc analysis of the SOLVD trials, warfarin was associated with a reduction of all-cause mortality, risk of death, and HF hospitalization (P=0.0006). However, there was no reduction in the incidence of VTE.14 Likewise aspirin was associated with a decrease in all-cause mortality (P=0.0005), risk of death, and HF hospitalization, and these effects were significant in the placebo but not in the enalapril group. Aspirin also was associated with lower VTE incidence, which was statistically significant in women, with a 53% relative risk reduction (P=0.03).30 In V-HeFT I and II, which included patients either in sinus rhythm or with AF, anticoagulation had no protective effect on VTE. Indeed, the VTE incidence was higher in patients treated with warfarin than in those without anticoagulant therapy (P=0.01). In V-HeFT I, a trend toward VTE reduction was observed in patients treated with aspirin compared with those not treated with antiplatelet therapy (P=0.07), but these associations were not present in the V-HeFT II (P=0.48).6

Thus, anticoagulants or antiplatelet agents did not show a clear benefit in survival and VTE risk in retrospective analyses of HF RCTs. Different results have been shown in
post-MI trials. In the SAVE trial, warfarin use was associated with an 81% reduction in the stroke risk ($P=0.001$), and patients taking aspirin had a 56% lower incidence of stroke after MI, with the protective effect more evident in patients with LVEF $<28%$. One important caveat to retrospective analyses of warfarin therapy is that they do not systematically collect or monitor adequacy of anticoagulation (ie, time with a therapeutic international normalized ratio [INR]), making prospective studies of warfarin critical for understanding efficacy and safety.

**Prospective RCTs**
To date, 3 multicenter RCTs have investigated the safety and efficacy of antithrombotic therapy in HF. The Warfarin/Aspirin Study in Heart Failure (WASH) was an open-label trial with 3 arms that compared no antithrombotic therapy, aspirin (300 mg/d), or warfarin (target INR, 2.5) in 279 patients with HF (LVEF <35%) in sinus rhythm. The primary end point was the composite of death, nonfatal MI, and nonfatal stroke. There was no significant difference in the primary end point among the study groups. The mean INR throughout the follow-up period was 2.3. Over a mean follow-up of 27 months, there was a trend toward worse outcomes (cardiovascular hospitalization, especially worsening HF) among patients randomized to aspirin ($P<0.044$). The incidence of minor bleeding was greater in the aspirin and warfarin groups compared with the no antithrombotic treatment group ($P<0.033$). A trend toward increased systolic blood pressure was observed with aspirin. Overall, the study did not demonstrate superiority of warfarin over no antithrombotic therapy for any primary or secondary measure. Warfarin was generally associated with more favorable outcomes and fewer serious adverse events (except for minor bleeding events) than either aspirin or no antithrombotic therapy. Because of a low rate of enrollment, the study was terminated prematurely and, thus, was not powered to make conclusive statements.

In the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) study, 1587 patients with HF (LVEF $<35%$) in sinus rhythm were randomized to either open-label warfarin (target INR, 2.5) or double-blind, double-dummy treatment with either aspirin (162 mg/d) plus placebo or clopidogrel (75 mg/d) plus placebo. The primary outcome was the time to first occurrence of death, nonfatal MI, or nonfatal stroke. Among baseline characteristics, the only intergroup difference that reached statistical significance was the prevalence of diabetes, which was highest in the warfarin group (38%) and lowest in the clopidogrel group (31%). The mean INR was 2.6. No differences were found among the 3 study groups with regard to the primary outcome. However, warfarin was associated with fewer nonfatal strokes than aspirin or clopidogrel. More patients randomized to aspirin were hospitalized for worsening HF ($P<0.02$) compared with the warfarin group. Major and minor bleeding events were higher in the warfarin group than in the clopidogrel group ($P<0.01$ and $P<0.025$, respectively) and the aspirin group ($P=0.22$ and $P=0.054$, respectively). Thus, the WATCH trial did not show that warfarin is superior to aspirin or that clopidogrel is superior to aspirin with regard to reduction of major cardiovascular event rate. The higher number of patients with diabetes in the warfarin group, with their higher risk, could have confounded the effectiveness of warfarin with regard to VTE reduction. As with WASH, the WATCH study was stopped prematurely because of a low rate of enrollment and, therefore, lacked power to make conclusive statements.

A meta-analysis of the data from WATCH and WASH studies found a modest trend in favor of lower mortality rate with warfarin compared with aspirin and suggested that a substantial difference in mortality or vascular events cannot be excluded (Figure 2); however, these findings are driven primarily by WATCH results because of its much larger sample size relative to WASH (1587 versus 279). A potentially important observation was an increased rate of hospitalizations in the aspirin group compared with warfarin group, which suggests a possible negative interaction between aspirin and ACE-inhibitors.

The Heart Failure Long-Term Antithrombotic Study was conducted in 197 patients with HF (LVEF $<35%$) in sinus rhythm. Patients with ischemic heart disease were random-
ized to receive either aspirin (325 mg/d) or warfarin (target INR, 2 to 3). Patients with dilated cardiomyopathy were randomized to receive either warfarin (target INR, 2.5) or placebo. Primary end points were nonfatal stroke, PE, MI, rehospitalization, HF exacerbation, or all-cause death. Patients with dilated cardiomyopathy were younger, were more likely to be women, and had lower LVEF and larger LV end-diastolic and end-systolic volume compared with those with ischemic heart disease. Baseline medication did not differ markedly between groups. The incidence of primary end points was not different between the groups; however, there was a trend toward benefit for warfarin over placebo in the dilated cardiomyopathy group. During 2 years of follow-up, the event rate was very low. This study also was underpowered to make definitive conclusions.34

Taken together, these 3 RCTs show that VTE is rare in patients with HF in sinus rhythm regardless of treatment. Although they suggest a possible benefit of warfarin, all these studies were underpowered to provide definitive evidence.

The Warfarin Aspirin Reduced Cardiac Ejection Fraction is a multicenter, randomized, double-blind trial in patients with HF (LVEF <35%) in sinus rhythm (target, 2860 patients) designed to test the primary null hypothesis of no difference between warfarin (target INR, 2.5 to 3) and aspirin (325 mg/d) in 3- to 5-year event-free survival for the composite end point of death or stroke. Secondary analyses will compare warfarin and aspirin for reduction of all-cause mortality, ischemic stroke, and MI balanced against the risk of intracerebral hemorrhage and focus on women and blacks and will compare warfarin and aspirin for prevention of stroke alone.35 Recruitment is ongoing. RCTs on antithrombotics in HF are summarized in Table 2.

### Does Aspirin Adversely Influence Outcomes in HF?

Previous analyses and RCTs have suggested a potential untoward effect of aspirin on HF hospitalizations. Prostaglandins, which cause vasodilation of the afferent arterioles of the glomeruli, are negatively affected by aspirin. Moreover, an interaction between aspirin and ACE-inhibitors is possible. One potential mechanism is that aspirin may inhibit prostaglandin synthesis, blunting the vasodilator effects of ACE-

### Table 2. RCTs on Antiplatelet vs Anticoagulation Therapy in HF

<table>
<thead>
<tr>
<th>RCT</th>
<th>No. Patients</th>
<th>Therapy</th>
<th>End Points</th>
<th>Results/Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>HELAS*</td>
<td>197</td>
<td>IHD: warfarin (INR, 2–3) vs aspirin (325 mg)</td>
<td>Death, stroke, re-MI</td>
<td>Trend toward benefit with warfarin in IHD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DCM: warfarin (INR, 2.5) vs placebo</td>
<td>Rehospitalization, PE, HF exacerbation</td>
<td></td>
</tr>
<tr>
<td>WASH*</td>
<td>279</td>
<td>Warfarin (INR, 2–3) vs aspirin (300 mg)</td>
<td>Death, MI, stroke</td>
<td>More HF hospitalization with aspirin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>More major bleeding with warfarin</td>
</tr>
<tr>
<td>WATCH*</td>
<td>1587</td>
<td>Warfarin (INR, 2–3) vs aspirin (162.5 mg)/clopidogrel (75 mg)</td>
<td>Death, MI, stroke</td>
<td>More HF hospitalization with aspirin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>More major bleeding with warfarin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fewer strokes with warfarin</td>
</tr>
<tr>
<td>WARCEF</td>
<td>2860 (target)</td>
<td>Warfarin (INR, 2.5–3) vs aspirin (325 mg)</td>
<td>Death, stroke</td>
<td></td>
</tr>
</tbody>
</table>

DCM indicates dilated cardiomyopathy; HELAS, Heart Failure Long-term Antithrombotic Study; IHD, ischemic heart disease; INR, international normalized ratio; MI, myocardial infarction; PE, pulmonary embolism; WARCEF, Warfarin Aspirin Reduced Cardiac Ejection Fraction; WASH, Warfarin/Aspirin Study in Heart Failure; WATCH, Warfarin and Antiplatelet Therapy in Chronic Heart Failure. Other abbreviations as in Table 1.

*No significant difference—underpowered.

inhibitors.36 This has led to the hypothesis that aspirin is harmful in HF.

In addition to the RCTs previously described, untoward effects of aspirin have been suggested by other studies. In SOLVD, antiplatelet agents were associated with an 18% reduction in all-cause mortality (P=0.0005). This beneficial effect was seen especially in women, who had a 53% reduction in VTE risk (P=0.03) compared with only 23% in men (P=0.06).14 However, a potential interaction between antiplatelet therapy and enalapril was detected, with patients taking antiplatelet therapy and randomized to enalapril experiencing no mortality benefit. Similarly, in the Cooperative New Scandinavian Enalapril Survival Study II, patients receiving aspirin experienced a significant increase in mortality with enalapril treatment (P=0.047), whereas those not receiving aspirin experienced no effect.37

A recent analysis of the Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients With Heart Failure registry did not find any statistically significant association between the combination of aspirin and ACE-inhibitors or angiotensin-II receptor blockers and adverse effects on intermediate postdischarge outcomes.38 Similarly, an analysis from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity program failed to show an interaction between aspirin administration (4246 patients [55.9%]) and the effects of candesartan compared with placebo on cardiovascular event rates (hazard ratio for the primary outcome in the patients receiving aspirin, 0.81; 95% CI, 0.72 to 0.90; hazard ratio in the others, 0.81; 95% CI, 0.72 to 0.91). There was also no interaction between aspirin and candesartan with regard to discontinuation of the study drug because of adverse reactions. The authors concluded that there seems to be no significant modification of the benefit of candesartan on cardiovascular mortality and morbidity outcomes or safety by concomitant use of aspirin in patients with chronic HF.39

A retrospective, systematic review of 6 long-term RCTs on HF treatment with ACE-inhibitors (SAVE, Trandolapril Cardiac Evaluation, Acute Infarction Ramipril Efficacy, SOLVD, and Heart Outcomes Prevention and Evaluation) did not show any significant differences in the major clinical outcomes in the presence or absence of aspirin administra-
tion. A Cochrane systematic review of trials of antiplatelet agents versus control or anticoagulants for patients with HF in sinus rhythm found no evidence to recommend routine use of aspirin to prevent thromboembolism and a possible adverse interaction with ACE-inhibitors. Moreover, when compared with aspirin, there was some evidence to indicate superior effects of warfarin with regard to hospitalizations. However, these analyses are limited by several factors: retrospective nature of the studies, antiplatelet agent use not having been randomized, the insufficient number of either VTE or patients enrolled, and the 3 RCTs to date being terminated prematurely and being underpowered to give definitive recommendations. Therefore, we lack conclusive data with regard to the impact of different antiplatelet agents on outcomes in patients with HF.

Can Clopidogrel Positively Influence Outcomes in HF?

Therapy with clopidogrel has been demonstrated to inhibit platelet indexes independently of HF etiology, New York Heart Association functional class, or LVEF. Notably, Bonde et al recently demonstrated with the National Patient Register of 56,994 first-documented MIs in Denmark a significant positive impact of clopidogrel on mortality in patients with HF after MI (5050) (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P = 0.002) (mean follow-up of 1.5 years) (Figure 3). Although these observational data raise an interesting hypothesis about the potential role for clopidogrel in HF, such a concept would need to be evaluated in a prospective RCT.

Current Guidelines and Practical Recommendations

The European Society of Cardiology guidelines state that there is no proven role for anticoagulation in HF. However, anticoagulants have been demonstrated to be more effective than antiplatelet agents in reducing the risk of stroke; thus, they are the preferred agents in patients with >1 moderate risk factor (eg, LVEF ≤35%, age ≥75 years, hypertension, diabetes mellitus) and for primary VTE prevention in patients with HF and AF and without any additional risk factors. With respect to antiplatelet agents, the guidelines state that (1) they are not as effective as anticoagulants in reducing VTE risk in patients with AF, (2) the risk of HF hospitalization has been shown to be significantly greater in aspirin-treated than in warfarin-treated patients, and (3) there is no evidence that antiplatelet agents reduce atherosclerotic risk in HF.

The American College of Cardiology/American Heart Association guidelines state that anticoagulation should be considered in patients with HF who have experienced a previous VTE or who have paroxysmal or persistent AF, in patients with underlying disorders that may be associated with an increased VTE risk, or in patients with familial dilated cardiomyopathy and a history of VTE in first-degree relatives. With regard to antiplatelet agents, the guidelines state that they should be used for MI and prevention of death in patients with HF with known coronary artery disease. However, they also state that the role of aspirin in HF has not been established, and concerns have been raised that it may attenuate the hemodynamic and survival benefits of ACE-inhibitors. Current guidelines are summarized in Table 3.

Table 3. Guidelines for Antithrombotic Therapy in HF

<table>
<thead>
<tr>
<th>Society</th>
<th>Recommendations</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC/AHA, 2009</td>
<td>Anticoagulants in patients with HF and paroxysmal or persistent AF or previous VTE</td>
<td>I-A</td>
</tr>
<tr>
<td></td>
<td>Antiplatelet agents for MI and death prevention in patients with HF and CAD</td>
<td>I-B</td>
</tr>
<tr>
<td></td>
<td>Anticoagulants in patients with underlying disorders that may be associated with increased VTE risk (eg, amyloidosis) and in patients with familial DCM and history of VTE in first-degree relatives</td>
<td>IIb-B</td>
</tr>
<tr>
<td>ESC, 2008</td>
<td>Anticoagulants for patients with &gt;1 moderate risk factor (age ≥75 years, hypertension, LVEF ≤35%, diabetes mellitus)</td>
<td>I-A</td>
</tr>
<tr>
<td></td>
<td>Aspirin or vitamin K antagonist for primary VTE prevention in patients of HF with AF without additional risk factors</td>
<td>I-A</td>
</tr>
</tbody>
</table>

ACC/AHA indicates American College of Cardiology/American Heart Association; CAD, coronary artery disease; ESC, European Society of Cardiology. Other abbreviations as in Tables 1 and 2.
Unanswered Questions and Future Directions
Several aspects of the pathophysiology of HF could explain VTE predisposition seen in this patient population. However, estimates of the incidence of VTE in patients with HF have varied widely. Additionally, appropriate management strategies to mitigate the risk of VTE remain uncertain for many groups of patients with HF. Three RCTs evaluating the use of antithrombotic therapy in ambulatory patients with HF have been inconclusive, and another RCT is ongoing. Patients at high risk for VTE, such as those with AF, previous VTE, LV thrombi, and underlying conditions predisposing to VTE, should be considered for antithrombotic therapy.

Antiplatelet therapy with aspirin remains an area of controversy and debate. For patients with nonischemic cardiomyopathy, there does not appear to be a role for the routine use of aspirin. For patients with HF and coronary artery disease, a more individualized approach should be considered, potentially using aspirin in those with recent coronary events, procedures, or current angina but not necessarily in those with a distant history of MI. In patients with advanced HF and coronary artery disease, especially if they require frequent hospital admissions despite optimal medical therapy, an alternative antithrombotic agent to aspirin should be considered.

Thus, it is difficult to make decisions about the administration of antithrombotic therapy to patients with HF. Moreover, a large number of alternative anticoagulants and antiplatelet agents currently are being developed (eg, direct thrombin inhibitors, factor Xa inhibitors, thrombin receptor antagonists, thromboxane receptor antagonists), and they may require a reassessment of the role of these agents in HF. RCTs are needed to specifically address the advantages and disadvantages of each antithrombotic regimen (efficacy, bleeding risk, costs) for the different clinical conditions associated with HF.

Disclosures
Dr Fiuszt is a consultant and shareholder of ARCA Biopharma, Inc, and a consultant for Roche Diagnostics and Forest Laboratories. Dr Richard Becker is a consultant for BMS, Boehringer-Ingelheim, Merk, Takeda, and Daiichi-Sankyo, Dr Felker is a consultant for Roche Diagnostics, Amgen, Otsuka, Corthera, Cytokinetics, and Genentech. Dr O’Connor is a consultant for Forest Laboratories, Roche Diagnostics, Amgen, Medpace, Hoffman La-Roche, Trevena, Actelion, GE Healthcare, Merck Pharmaceuticals, and Medtronic. Drs Bettari and Metra have no conflicts to disclose.

References


Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm: Current Status and Future Directions
Luca Bettari, Mona Fiuzat, Richard Becker, G. Michael Felker, Marco Metra and Christopher M. O’Connor

Circ Heart Fail. 2011;4:361-368
doi: 10.1161/CIRCHEARTFAILURE.110.959957

Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/4/3/361

An erratum has been published regarding this article. Please see the attached page for:
/content/4/5/e19.full.pdf

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/

On page 362, this sentence should read, “Overall, the 4-year survival analysis found that VTE rate was 4.0%, with an annual incidence of 1%.11 This sentence cites the correct reference.

The online version of the article has been corrected. The authors regret this error.

DOI: 10.1161/HHF.0b013e31822f88cd